Cohort III-2 120,492 Aim: to develop a model for In the new model, increased risk for () preeclampsia based on maternal preeclampsia, with a consequent shift demographic characteristics and in the Gaussian distribution of the medical history. gestational age at delivery with preeclampsia to the left, is provided Methods: Singleton pregnancies at by advancing maternal age, 13 weeks' gestation (2704 [2.2%] with increasing weight, Afro-Caribbean preeclampsia. A survival-time model for and South Asian racial origin, medical the gestational age at delivery with history of chronic hypertension, preeclampsia was developed from diabetes mellitus and systemic lupus variables of maternal characteristics erythematosus or antiphospholipid and history. This approach assumes syndrome, family history and personal that, if the pregnancy was to continue history of preeclampsia, and indefinitely, all women would conception by IVF. The risk for experience preeclampsia and that preeclampsia decreases with whether they do so or not before a increasing maternal height and in specified gestational age depends on parous women with no previous competition between delivery before preeclampsia. At a screen-positive or after development of preeclampsia. rate of 11%, as defined by NICE, the A 5-fold cross validation study was new model predicted 40%, 48%, and conducted to compare the 54% of cases of total preeclampsia performance of the new model with and preeclampsia requiring delivery the National Institute for Health and at <37 and <34 weeks' gestation, Clinical Excellence (NICE) guidelines. respectively, which were significantly higher than the respective values of 35%, 40%, and 44% achieved by application of NICE guidelines.
() Cohort III-2 120,492 Aim: to develop a model for preeclampsia based on maternal demographic characteristics and medical history. Methods: Singleton pregnancies at weeks' gestation (2704 [2.2%] with preeclampsia. A survival-time model for the gestational age at delivery with preeclampsia was developed from variables of maternal characteristics and history. This approach assumes that, if the pregnancy was to continue indefinitely, all women would experience preeclampsia and that whether they do so or not before a specified gestational age depends on competition between delivery before or after development of preeclampsia. A 5-fold cross validation study was conducted to compare the performance of the new model with the National Institute for Health and Clinical Excellence (NICE) guidelines. In the new model, increased risk for preeclampsia, with a consequent shift in the Gaussian distribution of the gestational age at delivery with preeclampsia to the left, is provided by advancing maternal age, increasing weight, Afro-Caribbean and South Asian racial origin, medical history of chronic hypertension, diabetes mellitus and systemic lupus erythematosus or antiphospholipid syndrome, family history and personal history of preeclampsia, and conception by IVF. The risk for preeclampsia decreases with increasing maternal height and in parous women with no previous preeclampsia. At a screen-positive rate of 11%, as defined by NICE, the new model predicted 40%, 48%, and 54% of cases of total preeclampsia and preeclampsia requiring delivery at <37 and <34 weeks' gestation, respectively, which were significantly higher than the respective values of 35%, 40%, and 44% achieved by application of NICE guidelines. 13
Preeclampsia%20evaluation%20report%2016May17.docx